The original success of Sildenafil undeniably revolutionized the drug landscape, but betting in companies primarily reliant on generic versions presents a challenging picture. Despite early profits were substantial, the expiration of patents and the emergence of less expensive alternatives have weakened market share. Therefore, a thorough assessmen